Emma Tallantyre, MD, PhD, Cardiff University, Cardiff, UK, discusses the use of antiCD20 monoclonal antibodies (mAbs) as a longterm treatment for multiple sclerosis (MS). The use of antiCD20 mAbs is a relatively new treatment for MS; therefore, it is difficult to confirm their safety as there is currently a lack of clinical evidence. Despite multiple Phase III trials showing favorable safety data for antiCD20 mAbs, there is a definite need for further studies into longterm treatment. There is evidence in the longterm use of rituximab and ocrelizumab showing depletion of IgG in many MS patients, as well as a considerable depletion of IgM. However, the reduction in IgG has not been observed in ofatumumab to the same extent. Therefore, the clinical products of biomarkers such as IgG need to be studied to ascertain whether the longterm use of antiCD20 mAbs is safe. Dr Tallantyre suggests that a more personalized use of antiCD20 mAbs could promote safer longterm use, although this raises concerns about the return of disease activity during a longer dose interval. This interview took place during the 2022 Multiple Sclerosis at the Limits Conference in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.